EGFR and lung adenocarcinoma: On the other hand, exon-20 insertions account for ~5% of all EGFR mutations and define a distinct subset of lung adenocarcinoma characterized by a poor response to the first-generation EGFR-TKIs gefitinib and erlotinib [9–11].